Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 18/20 | 0.80 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.54 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.54 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.54 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.54 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.54 |
| ▸ | RAF1 | P04049 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | RARA | P10276 | 1/20 | 0.51 |
| ▸ | RXRA | P19793 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1233322 | 0.89 | MAPK14 (1.00) | MAPK14RAF1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL2073899 | 0.84 | MAPK14 (1.00) | MAPK14RAF1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL29906734 | 0.83 | MAPK14 (0.57) | MAPK14RARARXRA | |
| SCHEMBL3839942 | 0.83 | MAPK14 (0.57) | MAPK14RARARXRA | |
| SCHEMBL1232255 | 0.83 | MAPK14 (0.81) | MAPK14RAF1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL2075591 | 0.79 | MAPK14 (1.00) | MAPK14RAF1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL2074433 | 0.78 | MAPK14 (1.00) | MAPK14RAF1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL15361999 | 0.75 | MAPK14 (0.82) | MAPK14RAF1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1874397 | 0.74 | PGR (0.55) | MAPK14 | |
| SCHEMBL1233438 | 0.74 | MAPK14 (0.64) | MAPK14RAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772288-B2 | Substituted spiro[cycloalkyl-1,3′-indo]-2′(1′H)-one derivatives and their use as P38 mitogen-activated kinase inhibitors | ALMIRALL, S.A. (ES) | 2014-07-08 | — | — | US | disclosed |
| US-8772288-B2 | Substituted spiro[cycloalkyl-1,3′-indo]-2′(1′H)-one derivatives and their use as P38 mitogen-activated kinase inhibitors | ALMIRALL, S.A. (ES) | 2014-07-08 | — | — | US | disclosed |
| US-8772288-B2 | Substituted spiro[cycloalkyl-1,3′-indo]-2′(1′H)-one derivatives and their use as P38 mitogen-activated kinase inhibitors | ALMIRALL, S.A. (ES) | 2014-07-08 | — | — | US | disclosed |
| EP-2280943-B1 | NEW SUBSTITUTED SPIRO[CYCLOALKYL-1,3'-INDO]-2'(1'H)-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS | ALMIRALL SA (ES) | 2013-11-06 | — | — | EP | disclosed |
| US-20110053936-A1 | SUBSTITUTED SPIRO[CYCLOALKYL-1,3'-INDOL]-2'(1'H)-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS | ALMIRALL, S.A. (ES) | 2011-03-03 | — | — | US | disclosed |
| US-20110053936-A1 | SUBSTITUTED SPIRO[CYCLOALKYL-1,3'-INDOL]-2'(1'H)-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS | ALMIRALL, S.A. (ES) | 2011-03-03 | — | — | US | disclosed |
| US-20110053936-A1 | SUBSTITUTED SPIRO[CYCLOALKYL-1,3'-INDOL]-2'(1'H)-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS | ALMIRALL, S.A. (ES) | 2011-03-03 | — | — | US | disclosed |
| EP-2280943-A1 | NEW SUBSTITUTED SPIROÝCYCLOALKYL-1,3'-INDOL¨-2'(1'H)-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS. | Almirall, S.A. (ES) | 2011-02-09 | — | — | EP | disclosed |
| WO-2009124692-A1 | NEW SUBSTITUTED SPIRO[CYCLOALKYL-1,3'-INDOL]-2'(1'H)-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS. | ALMIRALL, S.A. (ES) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009124692-A1 | NEW SUBSTITUTED SPIRO[CYCLOALKYL-1,3'-INDOL]-2'(1'H)-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS. | ALMIRALL, S.A. (ES) | 2009-10-15 | — | — | WO | disclosed |
| EP-2108641-A1 | New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors | Laboratorios Almirall, S.A. (ES) | 2009-10-14 | — | — | EP | disclosed |
| EP-2108641-A1 | New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors | Laboratorios Almirall, S.A. (ES) | 2009-10-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053936-A1 | SUBSTITUTED SPIRO[CYCLOALKYL-1,3'-INDOL]-2'(1'H)-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS | MAPK1, MAP3K1, MAP3K7 | MAPK14 25/4885GRIK1 834/4885GRIA1 891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.